Patient characteristics
| Baseline characteristics | All patients n=51 |
| Age | |
| Median | 64 |
| Range | (31 to 82) |
| Sex | |
| Male | 23 (45%) |
| Female | 28 (55%) |
| Race | |
| White | 41 (80%) |
| Black or African American | 9 (18%) |
| Other | 1 (2%) |
| Smoking | |
| Current/former | 43 (84%) |
| Never | 8 (16%) |
| Histology | |
| Adenocarcinoma | 31 (61%) |
| Squamous | 20 (39%) |
| ECOG performance | |
| 0 | 11 (22%) |
| 1 | 23 (45%) |
| >2 | 17 (33%) |
| Immunotherapy treatment | |
| Nivolumab | 35 (69%) |
| Pembrolizumab | 14 (27%) |
| Atezolizumab | 2 (4%) |
| Previous lines of therapy | |
| 1 | 23 (45%) |
| 2 | 11 (22%) |
| >3 | 17 (33%) |
ECOG, Eastern Cooperative Oncology Group .